Exagen Gross Profit vs. Return On Asset

XGN Stock  USD 4.23  0.19  4.30%   
Considering Exagen's profitability and operating efficiency indicators, Exagen Inc may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Exagen's ability to earn profits and add value for shareholders.
 
Gross Profit  
First Reported
2013-03-31
Previous Quarter
9.1 M
Current Value
M
Quarterly Volatility
2.8 M
 
Yuan Drop
 
Covid
As of the 11th of December 2024, Sales General And Administrative To Revenue is likely to grow to 1.51, while Price To Sales Ratio is likely to drop 0.64. At this time, Exagen's Income Tax Expense is very stable compared to the past year. As of the 11th of December 2024, Non Operating Income Net Other is likely to grow to about 19.3 K, while Operating Income is likely to drop (24 M).
For Exagen profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Exagen to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Exagen Inc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Exagen's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Exagen Inc over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.94)
Revenue Per Share
3.163
Quarterly Revenue Growth
0.066
Return On Assets
(0.17)
Return On Equity
(0.70)
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Exagen Inc Return On Asset vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Exagen's current stock value. Our valuation model uses many indicators to compare Exagen value to that of its competitors to determine the firm's financial worth.
Exagen Inc is rated below average in gross profit category among its peers. It is rated below average in return on asset category among its peers . At this time, Exagen's Gross Profit is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Exagen's earnings, one of the primary drivers of an investment's value.

Exagen Return On Asset vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Exagen

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
21.35 M
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Exagen

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.17
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Exagen Return On Asset Comparison

Exagen is currently under evaluation in return on asset category among its peers.

Exagen Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Exagen, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Exagen will eventually generate negative long term returns. The profitability progress is the general direction of Exagen's change in net profit over the period of time. It can combine multiple indicators of Exagen, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-22.8 M-24 M
Income Before Tax-23.7 M-24.8 M
Total Other Income Expense Net-819 K-860 K
Net Loss-23.7 M-24.9 M
Income Tax Expense33 K34.6 K
Interest Income1.5 M989.2 K
Net Loss-42.6 M-40.5 M
Net Loss-32.5 M-34.1 M
Non Operating Income Net Other18.4 K19.3 K
Net Interest Income-1.6 M-1.6 M
Change To Netincome13.6 M14.3 M
Net Loss(1.34)(1.41)
Income Quality 0.61  0.81 
Net Income Per E B T 1.00  1.10 

Exagen Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Exagen. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Exagen position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Exagen's important profitability drivers and their relationship over time.

Use Exagen in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.

Exagen Pair Trading

Exagen Inc Pair Trading Analysis

The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.
The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Exagen position

In addition to having Exagen in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Money Market Funds Thematic Idea Now

Money Market Funds
Money Market Funds Theme
Funds or Etfs investing in various types of short-term (less than one year) fixed income instruments of high-quality and liquidity. The Money Market Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Market Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:
Check out Your Current Watchlist.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
To fully project Exagen's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Exagen Inc at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Exagen's income statement, its balance sheet, and the statement of cash flows.
Potential Exagen investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Exagen investors may work on each financial statement separately, they are all related. The changes in Exagen's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Exagen's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.